This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–2851.
Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients With previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 1998; 91: 3607–3615.
Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100: 3869–3876.
Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854–4860.
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999; 107: 69–79.
Ferguson P, Hills R, Grech A, Betteridge S, Kjeldsen L, Dennis M et al. An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients for whom allogeneic stem cell transplantation represents the only curative therapy. Blood 2015; 126: 559 (ASH abstract).
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64–70.
Ravandi F, Cortes J, Faderl S, O’Brien S, Garcia-Manero G, Verstovsek S et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010; 116: 5818–5823.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Othus, M., Mukherjee, S., Sekeres, M. et al. Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30, 1779–1780 (2016). https://doi.org/10.1038/leu.2016.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.48
This article is cited by
-
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies
Leukemia (2022)
-
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT
Bone Marrow Transplantation (2022)
-
Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia
International Journal of Hematology (2021)
-
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Leukemia (2017)
-
How many cycles of 7+3 and for whom?
Leukemia (2016)